Literature DB >> 32725114

Inhibition of MMP prevents doxorubicin-induced cardiotoxicity by attenuating cardiac intracellular and extracellular matrix remodelling.

Inna Rabinovich-Nikitin1, Matthew Love1, Lorrie A Kirshenbaum1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 32725114      PMCID： PMC7797205          DOI： 10.1093/cvr/cvaa198

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  10 in total

1.  Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.

Authors:  P Altieri; C Brunelli; S Garibaldi; A Nicolino; S Ubaldi; P Spallarossa; L Olivotti; P Rossettin; A Barsotti; G Ghigliotti
Journal:  Eur J Clin Invest       Date:  2003-08       Impact factor: 4.686

2.  Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury.

Authors:  Wenjie Wang; Costas J Schulze; Wilma L Suarez-Pinzon; Jason R B Dyck; Grzegorz Sawicki; Richard Schulz
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

Review 3.  Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.

Authors:  Arthur Winer; Sylvia Adams; Paolo Mignatti
Journal:  Mol Cancer Ther       Date:  2018-05-07       Impact factor: 6.261

4.  Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Authors:  Mohammad A M Ali; Woo Jung Cho; Bryan Hudson; Zamaneh Kassiri; Henk Granzier; Richard Schulz
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

5.  MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling.

Authors:  Brandon Y H Chan; Andrej Roczkowsky; Woo Jung Cho; Mathieu Poirier; Consolato Sergi; Vic Keschrumrus; Jared M Churko; Henk Granzier; Richard Schulz
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

6.  Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling.

Authors:  Rimpy Dhingra; Victoria Margulets; Subir Roy Chowdhury; James Thliveris; Davinder Jassal; Paul Fernyhough; Gerald W Dorn; Lorrie A Kirshenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

Review 7.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

8.  Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.

Authors:  Faryar Foroodi; Wilhelmina C Duivenvoorden; Gurmit Singh
Journal:  Anticancer Drugs       Date:  2009-02       Impact factor: 2.248

9.  Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes.

Authors:  Brandon Y H Chan; Andrej Roczkowsky; Nils Moser; Mathieu Poirier; Bryan G Hughes; Ramses Ilarraza; Richard Schulz
Journal:  Can J Physiol Pharmacol       Date:  2018-10-11       Impact factor: 2.273

Review 10.  Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.

Authors:  Becky Meiners; Chetan Shenoy; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2018-08-29       Impact factor: 5.027
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.